Novavax, Inc. (NVAX) Given Average Rating of “Hold” by Brokerages

Novavax, Inc. (NASDAQ:NVAX) has earned a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $3.43.

A number of equities research analysts have recently commented on the company. Seaport Global Securities restated a “neutral” rating on shares of Novavax in a research report on Friday, October 6th. Zacks Investment Research cut Novavax from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 price objective on shares of Novavax in a report on Wednesday, November 8th. BidaskClub upgraded Novavax from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Finally, Citigroup upgraded Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price objective on the stock in a report on Tuesday, October 31st.

Novavax (NASDAQ:NVAX) traded up $0.02 during trading hours on Thursday, hitting $1.36. The stock had a trading volume of 2,849,527 shares, compared to its average volume of 5,966,049. Novavax has a 52-week low of $0.73 and a 52-week high of $1.78. The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31.

Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.01. Novavax had a negative return on equity of 787.38% and a negative net margin of 726.35%. The firm had revenue of $8.35 million for the quarter, compared to analysts’ expectations of $6.42 million. During the same period last year, the firm earned ($0.24) EPS. The company’s quarterly revenue was up 158.5% on a year-over-year basis. analysts expect that Novavax will post -0.62 EPS for the current fiscal year.

In other news, insider Stanley C. Erck acquired 100,000 shares of the stock in a transaction that occurred on Thursday, November 9th. The shares were bought at an average cost of $1.13 per share, for a total transaction of $113,000.00. Following the acquisition, the insider now owns 228,279 shares in the company, valued at approximately $257,955.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.00% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Novavax by 4.5% in the 1st quarter. Vanguard Group Inc. now owns 21,681,318 shares of the biopharmaceutical company’s stock worth $27,752,000 after buying an additional 938,581 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Novavax by 40.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,196,508 shares of the biopharmaceutical company’s stock worth $5,976,000 after buying an additional 1,488,403 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Novavax by 2.8% during the 2nd quarter. Northern Trust Corp now owns 3,376,714 shares of the biopharmaceutical company’s stock worth $3,883,000 after purchasing an additional 92,854 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Novavax by 18.3% during the 1st quarter. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company’s stock worth $3,073,000 after purchasing an additional 371,295 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in shares of Novavax by 38.7% during the 2nd quarter. GSA Capital Partners LLP now owns 1,690,153 shares of the biopharmaceutical company’s stock worth $1,944,000 after purchasing an additional 471,347 shares during the last quarter. Institutional investors own 36.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Novavax, Inc. (NVAX) Given Average Rating of “Hold” by Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/11/30/novavax-inc-nvax-given-average-rating-of-hold-by-brokerages.html.

Novavax Company Profile

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply